DaVita Inc.
DVA
Positions held
Your positionsDVA isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- DaVita Inc. operates in a growing healthcare sector, focusing on kidney care, which is increasingly vital as the population ages and chronic kidney disease rates rise.
- DaVita's revenue grew by 4% compared to the prior quarter, reaching $3.6 billion.
- The company's operating margin expanded to 16.1%, up from 13.9% in the previous quarter.
- The company has a high debt-to-equity ratio of 1241.986, indicating potential financial risk.
- DaVita's trailing P/E ratio is 15.24, which may suggest the stock is overvalued compared to its earnings growth.
- The stock has a 52-week range of $101.00 to $247.49, indicating significant volatility.
Fundamentals
| Market cap | $11.29B | Enterprise value | $25.86B | Trailing P/E | 14.95 | Forward P/E | 10.33 |
| PEG | 0.43 | Price / book | -14.80 | Beta | 0.80 | Dividend yield | 0.00% |
| Revenue growth | 5.2% | Earnings growth | 55.8% | Gross margin | 32.4% | Operating margin | 16.1% |
| Profit margin | 6.0% | ROE | 88.5% | ROA | 7.5% | Debt / equity | 12.42 |
| Current ratio | 1.47 | Free cash flow | $1.04B | Analyst recommendation | buy | Mean target | $219.86 |
| 52w high | $247.49 | 52w low | $101.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $3.6B | $3.4B | $3.6B | $3.4B | $3.4B | — |
| Op margin | 16.1% | 13.9% | 15.2% | 14.5% | 15.7% | — |
| Net income | $265M | $198M | $234M | $150M | $199M | — |
| Gross margin | 32.7% | 31.4% | 33.4% | 31.8% | 33.1% | — |
| Gross profit | $1.2B | $1.1B | $1.2B | $1.1B | $1.1B | — |
| Operating income | $571M | $474M | $551M | $496M | $530M | — |
- Revenue +4% vs prior quarter ($3.6B vs $3.4B).
- Gross margin 32.7% (was 31.4% prior quarter).
- Operating margin expanded to 16.1%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $13.6B | $12.8B | $12.1B | $11.6B | — |
| Op margin | 14.7% | 15.3% | 13.2% | 11.3% | — |
| Net income | $747M | $936M | $692M | $560M | — |
| Gross margin | 32.2% | 32.9% | 31.5% | 29.3% | — |
| Gross profit | $4.4B | $4.2B | $3.8B | $3.4B | — |
| Operating income | $2.0B | $2.0B | $1.6B | $1.3B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Here's Why You Should Retain DaVita Stock in Your Portfolio for Now
2026-10-08 · DaVita Activates Emergency Response Efforts Ahead of Hurricane Isaias, Urges Kidney Patients to Prepare Early
2026-10-07 · Strength Seen in Option Care (OPCH): Can Its 32.7% Jump Turn into More Strength?
2026-10-02 · DaVita HealthCare (DVA) Laps the Stock Market: Here's Why
2026-09-30 · 3 Cash-Producing Stocks with Open Questions
2026-09-29 · DaVita (DVA) Stock May Be Undervalued On Its Earnings Power
2026-09-29 · This Warren Buffett Stock Is Up 58%. History Says This Is What Happens Next.
2026-09-24 · DaVita HealthCare (DVA) Registers a Bigger Fall Than the Market: Important Facts to Note
2026-09-24 · 1 Profitable Stock with Competitive Advantages and 2 That Underwhelm
2026-09-23 · Is DaVita Stock Underperforming the S&P 500?
2026-09-21 · AllianceBernstein Global High Income Fund, Inc. RELEASES MONTHLY PORTFOLIO UPDATE
2026-09-21 · 3 Surging Stocks That Don’t Need the AI Boom to Keep Winning
Price (daily)
Full chart · RSI · MACD · patterns